Home › SEC Filings
SEC Filing Analysis
All Current Report (8-K)Annual Report (10-K)Quarterly Report (10-Q)Form 4 Insider TradesSC 13D Beneficial Ownership13F Institutional HoldingsPress ReleasesInsider Cluster ActivityInsider Buy Activity
Theme?
All themes Artificial IntelligenceSemiconductorsQuantum ComputingSpace & SatellitesRobotics & AutomationElectric VehiclesClean & Renewable EnergyBattery & Energy StorageNuclear & FusionCybersecurityCloud & SaaSFintech & PaymentsCrypto & BlockchainGenomics & Gene EditingBiotech & Drug DiscoveryE-commerce & PlatformsStreaming & Digital MediaGaming & EsportsDefense TechCannabis
| Ticker | Type | Sentiment | Impact | Summary | Date |
|---|---|---|---|---|---|
| LNTH | 8-K, DEFA14A | bullish | 8/10 | Lantheus (LNTH) has entered into a definitive merger agreement with Curium US Holdings LLC, a private equity-backed radi | Aug 4, 2026 |
| ABVC | 8-K | neutral | 3/10 | ABVC BioPharma postponed the previously announced distribution of BioKey (Cayman) Inc. ordinary shares, which had been s | Aug 4, 2026 |
| XRTX | 6-K | neutral | 3/10 | XORTX Therapeutics filed a 6-K announcing the resignation of Anthony Giovinazzo from the board of directors for personal | Aug 4, 2026 |
| CRVO | PRESS-RELEASE | bullish | 4/10 | CervoMed announced that neflamapimod, its oral small-molecule candidate for dementia with Lewy bodies (DLB), has been gr | Aug 4, 2026 |
| TRDA | CLUSTER | neutral | 4/10 | Two insiders at Entrada Therapeutics (Director Kush Parmar and 10% owner 5AM Ventures) sold a combined $1.59M in open-ma | Aug 3, 2026 |
| ALKS | CLUSTER | neutral | 2/10 | Two Alkermes executives (EVP CLO and EVP R&D/CMO) sold a combined $536K in open-market shares on August 3, 2026, one wee | Aug 3, 2026 |
| ALKS | CLUSTER | neutral | 3/10 | Two Alkermes insiders (EVP R&D/CMO and EVP/CLO) sold a combined $536K in open-market shares on August 3, 2026, one week | Aug 3, 2026 |
| PGEN | CLUSTER | neutral | 2/10 | Precigen insiders (CFO and COO) sold a combined $826K in open-market sales over a 4-day window. The CFO sold $606K at $6 | Aug 3, 2026 |
| KLRS | 3 | neutral | 2/10 | Laurie Keating filed a Form 3 initial statement of beneficial ownership with Kalaris Therapeutics, along with a Power of | Aug 3, 2026 |
| KROS | 8-K | neutral | 4/10 | Keros Therapeutics reported Q2 2026 results with a net loss of $28.7M ($1.45/share), slightly narrower than the $30.7M l | Aug 3, 2026 |
| CYCN | 425 | neutral | 4/10 | Korsana Biosciences announced three senior leadership appointments (CMO, CTO, and a new Board member/Audit Chair) and re | Aug 3, 2026 |
| SUPN | DEFA14A, 425 | bullish | 7/10 | Supernus and Indivior announced an all-stock merger of equals to create a combined CNS biopharma company with ~$2.2B in | Aug 3, 2026 |
| STOK | 8-K | bearish | 6/10 | Stoke Therapeutics filed a prospectus supplement to sell up to $200 million of common stock in an at-the-market (ATM) of | Aug 3, 2026 |
| ARQT | 144 | neutral | 2/10 | Director Patrick Burnett filed a Form 144 notice of intent to sell 955 shares of Arcutis Biotherapeutics common stock, v | Aug 3, 2026 |
| APGE | DEFA14A | bullish | 5/10 | Apogee filed supplementary proxy materials (DEFA14A) on August 3, 2026, updating stockholders ahead of the August 11 spe | Aug 3, 2026 |
| SUPN | 8-K | bullish | 7/10 | Supernus Pharmaceuticals and Indivior have entered into an all-stock merger of equals, announced via employee communicat | Aug 3, 2026 |
| NXTC | INSIDER-BUY | bullish | 6/10 | ADAR1 Capital Management, LLC, a 10% owner, purchased approximately $1.43 million of NXTC shares over July 23-30, 2026, | Aug 3, 2026 |
| NRIX | CLUSTER | neutral | 2/10 | Three C-suite insiders at Nurix Therapeutics (NRIX) sold a combined $539K of stock in a 7-day window, representing only | Aug 3, 2026 |
| STOK | 424B5 | bearish | 6/10 | Stoke Therapeutics filed a 424B5 prospectus supplement to upsize its at-the-market (ATM) equity offering facility from $ | Aug 3, 2026 |
| CRNX | PRESS-RELEASE | bullish | 9/10 | No summary provided | Aug 3, 2026 |
| ORIC | PRESS-RELEASE | neutral | 5/10 | ORIC reported Q2 2026 net loss of $(0.38) per share, missing consensus of $(0.36) by $0.02. The operational highlight is | Aug 3, 2026 |
| CRSP | PRESS-RELEASE | bullish | 6/10 | CRISPR Therapeutics reported Q2 2026 GAAP EPS of -$0.94, beating consensus of -$1.10 by 14.5%, as CASGEVY revenue reache | Aug 3, 2026 |
| KROS | PRESS-RELEASE | neutral | 3/10 | Keros Therapeutics reported Q2 2026 net loss of $28.7M (EPS -$1.45), missing consensus EPS of -$1.24 and zero revenue vs | Aug 3, 2026 |
| MPLT | 144 | neutral | 2/10 | Officer Lillie James Woodruff filed a Form 144 notice to sell 22,082 shares of MapLight Therapeutics common stock, value | Aug 3, 2026 |
| NATR | PRESS-RELEASE | neutral | 2/10 | Nature's Sunshine appointed Janine Weber as EVP and President, North America, effective August 10, 2026. Weber brings ov | Aug 3, 2026 |
| RDY | 6-K | bullish | 6/10 | Dr. Reddy's announced U.S. FDA approval of its rituximab biosimilar (biosimilar to Rituxan) on the goal date, strengthen | Aug 3, 2026 |
| INDV | 425, 8-K | bullish | 7/10 | Indivior announces transformative all-stock merger of equals with Supernus Pharmaceuticals. Each Supernus share will con | Aug 3, 2026 |
| SUPN | DEFA14A, 425, 8-K | bullish | 8/10 | Supernus Pharmaceuticals has entered into a definitive agreement to merge with Indivior Pharmaceuticals in a tax-free al | Aug 3, 2026 |
| INDV | 425 | bullish | 8/10 | Indivior reported record Q2 2026 results with total net revenue of $343M (up 14% YoY), record SUBLOCADE net revenue of $ | Aug 3, 2026 |
| INDV | 8-K | bullish | 8/10 | Indivior reported record Q2 2026 results with total net revenue of $343M (+14% YoY), record SUBLOCADE net revenue of $25 | Aug 3, 2026 |